MIA researchers sharing world stage at ESMO24
MIA’s leading experts and early career researchers have shared the world stage at the annual European Society for Medical Oncology (ESMO) Congress in Barcelona.
MIA’s leading experts and early career researchers have shared the world stage at the annual European Society for Medical Oncology (ESMO) Congress in Barcelona.
Final results of the COMBI-AD clinical trial, published in New England Journal of Medicine, show significant benefit in preventing disease progression in BRAF positive Stage III melanoma patients.
Our 2024 Australians of the Year recently explored the Northern Territory, as part of a visit organised by the Australia Day Council. View the photo album.
In what has been described as a cancer treatment revolution, the pre-surgery use of combination immunotherapy looks to become standard treatment for melanoma and impact other cancers across the globe.
Congratulations to Professor Georgina Long AO, elected as a Fellow of the Australian Academy of Science in recognition of her outstanding contribution to science.
Listen to Profs Long and Scolyer on ABC Radio Sydney for an update on Richard's #braincancer journey & recent results. how melanoma science is being used to treat his #glioblastoma. Budget funding news and their Australian of the Year activities.
Last night's Federal Budget announcement included a $25 million commitment to prevention and early detection of skin cancer and melanoma, and $10.3 million has been allocated for MIA to develop an evidence-based roadmap for a targeted skin cancer screening program.
Read more about 'Skin Checks for Melanoma in Australia Position Statement’, led by MIA in collaboration with expert colleagues across Australia.
We are so proud of our MIA Co-Medical Directors, Prof Georgina Long AO and Prof Richard Scolyer AO, jointly named 2024 Australians of the Year.
The federal government has announced a new immunotherapy treatment for advanced melanoma patients has been added to PBS, significantly reducing the cost of the life-saving treatment.